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Individuals whose RBCs are characterized as having a partial D
phenotype may make anti-D if exposed to normal D+ RBCs; thus it
is desirable that they be typed as D– should they require blood
transfusion or Rh immune globulin (RhIG) prophylaxis. Further,
use of different anti-D reagents by blood centers and transfusion
services can account for FDA-reportable errors. For this study, anti-
D reagents for use in tube tests were obtained from three U.S.
manufacturers. They included three examples of IgM monoclonal
anti-D blended with monoclonal IgG anti-D, one IgM monoclonal
anti-D blended with polyclonal IgG anti-D, and two reagents
formulated with human anti-D in a high-protein diluent. One anti-
D formulated for use by gel column technology was also tested.
Direct agglutination tests by tube or gel were strongly positive
(scores 9–12), with partial D RBCs of types DII, DIIIa, DIIIb, and
DIVa. No reagent anti-D caused direct agglutination of DVI type 1,
DVI type 2, or DFR phenotype RBCs. One tube anti-D reagent
formulated with an IgM monoclonal anti-D plus a polyclonal IgG
anti-D failed to cause direct agglutination of DVa, DBT, and R0
Har
RBCs, while DVa RBCs reacted weakly with two high-protein
reagents formulated with human IgG anti-D. In contrast, the anti-D
used by gel column technology was strongly reactive (score 11)
with DVa, DBT, and R0
Har RBCs. The single monoclonal
IgM–polyclonal IgG blended anti-D and the two high-protein
reagents were also the only reagents that failed to react with R0
Har
RBCs by the IAT. Elimination of the test for weak D on all patient
samples, using currently available FDA-licensed reagents, will
ensure that partial D category VI (DVI) patients will type as D– for
the purpose of RhIG prophylaxis and blood transfusion. However,
RBCs of other partial D phenotypes will be classified as D+ in direct
agglutination tests with some, if not all, currently available reagents.
Testing donors for weak expression of D continues to be required,
albeit that Rh alloimmunization by RBCs with a weak or partial D
phenotype is uncommon. Further, because of differences in
performance characteristics among FDA-approved reagents,
conflicts between donor center D typing and transfusion service
confirmatory test results are inevitable. Immunohematology
2005;21:146–8.
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Flegel and Wagner1 have shown that weak D
phenotypes arise from missense mutations to regions
of the RHD gene that encode the transmembrane
portion of the D protein. Consequently, less than the
expected amount of normal D protein is inserted into
the RBC membrane. Individuals whose RBCs are
characterized as having a partial D phenotype usually
do not make anti-D if exposed to D+ RBCs and most
examples should type as D+ in direct agglutination
tests with currently available reagents formulated in
part with high-affinity IgM monoclonal anti-D.
In contrast, partial D phenotypes are the result of
hybrid genes or missense mutations to regions of RHD
that encode portions of D protein external to the RBC
membrane. Individuals with a partial D phenotype or
with RBCs expressing a partial D phenotype are at risk
of making anti-D if exposed to D+ RBCs. Therefore, it
is desirable that they be typed as D– if they are
candidates for transfusion or RhIG prophylaxis.
Further, partial D phenotypes can account for FDA-
reportable errors when blood centers and hospitals
use different reagents that give dissimilar reactions
with partial D phenotype RBCs.
To determine the performance characteristics of
anti-D reagents with respect to partial D phenotype
cells, we tested currently available FDA-approved
reagents. Our findings, which have implications for
both transfusion service and blood donor testing
laboratories, are presented in this report.
Materials and Methods
The partial D RBCs used in this investigation were
from our frozen RBC collections. Many had been
obtained through the SCARF International Exchange
Program.
Gel column technology using ABO and Rh typing
cards (preloaded with anti-D) was from Ortho-Clinical
Diagnostics, Raritan, New Jersey. Anti-D reagents for
tube testing included a monoclonal IgM anti-D blended
with polyclonal IgG anti-D (BioClone, Ortho) and three
monoclonal IgM anti-Ds blended with monoclonal IgG
anti-D (ImmucorGamma, Norcross, GA). The specific
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monoclonal antibodies used in the formulation of these
reagents are shown in Table 1. In addition, we tested
two anti-D reagents formulated in a high-protein
diluent with human IgG anti-D as well as their matched
inert control reagents (ImmucorGamma). All reagents
were used in accordance with the manufacturers’




The results of direct agglutination tests with anti-D
reagents and partial D RBCs are shown in Table 2. RBCs
of partial D categories II, IIIa, IIIb,and IVa were strongly
reactive (scores 9–12) with the five tube reagents and
with the anti-D used by gel column technology. RBCs
of categories DVI type 1 (BARC– [RH:–52]), DVI type 2
(BARC+ [RH:52]), and DFR (FPTT+ [RH:50])3 did not
react in direct tests with tube and with reagents used
by the gel column technology. The tube tests were also
examined for direct agglutination after incubation, as
permitted by the manufacturer; again no agglutination
was observed with the DVI and DFR samples.
Partial D RBCs of types DVa, DBT, and R0
Har did not
react with or were variably agglutinated by these
reagents. Of note is the failure of the Ortho tube
reagent to react with these RBCs in direct agglutination
tests while the same RBCs reacted strongly (score 11)
with the anti-D used by gel column technology
marketed by the same manufacturer. In contrast,
Gamma and Immucor monoclonal reagents reacted
with DVa and DBT RBCs in direct tests and they gave
weak and variable reactions with R0
Har RBCs; the direct
reactions with R0
Har RBCs were only slightly enhanced
after incubation.
Indirect Antiglobulin Test (IAT)
Partial D RBCs that reacted weakly or not at all with
one or more tube anti-D reagents in direct
agglutination tests were further tested against these
reagents by the IAT (test for weak D). The results are
summarized in Table 3. Gamma and Immucor reagents
formulated with monoclonal anti-D reacted with DVa,
DVI, DFR, and R0
Har RBCs; DBT RBCs were not tested by
IAT since these RBCs were strongly reactive in direct
agglutination tests. In contrast, reagents formulated
with human anti-D reacted with DVa, DVI, DFR, and
DBT, but not with R0
Har RBCs.
Discussion
To paraphrase Flegel and Wagner,1 it is desirable
that partial D RBCs, especially those of the most
commonly encountered form (DVI), be typed as D–
Table 1. Formulation of currently available FDA-approved anti-D reagents
Reagent Type Source IgM anti-D IgG anti-D
Tube Ortho BioClone MAD2 Polyclonal
Tube Gamma-clone GAMA401 F8D8
Tube Immucor Series 4 MS201 MS26
Tube Immucor Series 5 Th28 MS26
Gel Ortho (ID-MTS) MS201 NA*
* Not applicable
Table 3. Results of IATs with tube anti-D reagents and those partial D
RBCs that did not react in direct agglutination tests*
Monoclonal Anti-D Polyclonal anti-D†
Partial D 
RBCs GAM IMM-4/5 ORT GAM IMM
DVa 10 12 11 8 8
DVI.1 12 11 8 9 8
DVI.2 11 10 8 9 9
DFR 12 12 11 8 9
DBT /‡ / 8 9 9
R0
Har-1 9 9 0 0 0
R0
Har-2 10 10 0 0 0
R0
Har-3 8 8 0 0 0
*Agglutination score of IATs with anti-D.
†ORT is reagent formulated with IgM monoclonal anti-D and human IgG anti-D in a
low-protein diluent; GAM and IMM are both high-protein reagents formulated from
human IgG anti-D.
‡Not tested; RBCs directly agglutinated.
Table 2. Results of direct agglutination tests with IgM/IgG blended 
anti-D reagents and partial D RBCs*†
Monoclonal Polyclonal 
Anti-D Anti-D
GAM IMM-4 IMM-5 ORT ORT GAM IMM
Tube Tube Tube Tube Gel Tube Tube
DII 10 12 11 11 12 9 10
DIIIa 10 12 12 12 12 11 10
DIIIb 9 9 8 8 11 8 9
DIVa 9 12 10 12 12 10 10
DVa 6 9 8 0(0) 11 5 5
DVI.1 0(0) 0(0) 0(0) 0(0) 0 0 0
DVI.2 0(0) 0(0) 0(0) 0(0) 0 0 0
DFR 0(0) 0(0) 0(0) 0(0) 0 0 0
DBT 10 11 10 0(0) 11 0 0
R0
Har-1 6(8) 0(6) 0(0) 0(0) 12 0 0
R0
Har-2 6(6) 6(10) 6(10) 0(0) 12 0 0
R0
Har-3 3(4) 0(3) 0(3) 0(0) 9 0 0
*Agglutination score of direct tests with anti-D.
†Number in parentheses denotes agglutination score following incubation, as
permitted by the manufacturer.
Partial D
RBCs
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when the sample is from a patient who is pregnant or
requires transfusion. Such patients are at risk of
alloimmunization to D and should be transfused with
D– RBCs; if pregnant, they should receive appropriate
RhIG therapy. DVI RBCs can be appropriately typed as
D– by direct agglutination tests with any of the
currently available FDA-approved monoclonal anti-D
reagents. However,RBCs of some partial D phenotypes
(DII, DIIIa, DIIIb, and DIVa) typed as D+ in direct tests
with all anti-D reagents tested and yet other
phenotypes reacted variably.
The test for weak D (formerly Du) need not be
performed, nor is it required in a hospital setting
except for testing apparent (by direct agglutination
tests) D– newborns of D– women.4 Some
consideration should also be given to testing new
patients with more than one anti-D reagent, the second
test performed after reidentification of the sample to
prevent erroneous D typings due to sample
misidentification within the laboratory. The use of two
different anti-D reagents, based on data we have
presented, will facilitate recognition of potential R0
Har
samples. Conflicts between the two anti-D results, or
between current and historical records, may also be an
indication of partial D and the patient should be
managed accordingly.
The overall reactivity of Ortho’s tube reagent was
most consistent with that of the two high-protein
reagents formulated with human IgG anti-D. All three
reagents failed to react with R0
Har in both direct and
indirect tests, in contrast to the Gamma and Immucor
monoclonal reagents. However, it should be noted that
the reactivity of these reagents by IAT is due to carry-
over agglutination from direct tests (T. Frame, FIBMS,
personal communication, 2004).
Depending upon the reagents and method used,
conflicts between donor center D typing and
transfusion service confirmatory test results can be
expected, especially when testing DVa, DBT, and R0
Har
RBCs. Since these conflicts may be considered FDA-
reportable errors, managers of donor testing facilities
may want to give consideration to reagent selection
and their methods for testing for weak D. Reliable
detection of some partial D phenotypes appears to
require a tube test for weak D; we have no data on the
reactivity of tube anti-D reagents with partial D cells
when tested on automated platforms.
It should be noted that in most cases only a single
example of each partial D category was tested. That
there is undoubtedly heterogeneity among RBCs of a
particular category is evident from the variability of
reactions noted with three different examples of R0
Har
RBCs. R0
Har-1 was confirmed as such by both molecular
and serologic analysis; it tested positive for Rh33 and
Rh50. All three examples reacted with an eclectic
human anti-D known to react with R0
Har RBCs.
In conclusion, tests for weak D need not be
performed on apparent D– pregnant women or
potential transfusion recipients.4 Rather, such
individuals can be considered D– for the purpose of
RhIG prophylaxis and blood transfusion.5 While such a
testing strategy will appropriately type DVI RBCs (the
most common form of partial D) as D–, RBCs of other
partial D phenotypes will be classified as D+ in direct
agglutination tests with some, if not all, currently
available reagents. Testing donor blood for weak
expression of D continues to be required.4 Due to
differences in performance characteristics among FDA-
approved reagents, as revealed in this investigation,
conflicts between donor center D typing and trans-
fusion service confirmatory test results are inevitable.
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